Descargar Oncology Nursing Drug Handbook - v3.5.13

Has oído hablar de Oncology Nursing Drug Handbook - v3.5.13, o Medical Dictionary Free & Offline - Diseases, Dexcom G6, Pacify, iDentist Dental practice management, Patchwork, MCQ Abubakr (ASU), uno de los Aplicaciones más interesantes de la categoría Medicina.

Y, por supuesto, sabes que no todos los juegos o aplicaciones son compatibles con todos los teléfonos. El juego o la aplicación a veces no está disponible en tu dispositivo, depende de la versión del sistema. Sistema operativo Android, resolución de pantalla o países a los que Google Play permite el acceso. Es por eso que APKPanda proporciona archivos APK de Android para que los descargues y no cumple estas restricciones.>
Oncology Nursing Drug Handbook - v3.5.13 la última versión es 3.5.13, la fecha de lanzamiento 2020-06-25 y tiene el tamaño 8.4 MBDesarrollado por Skyscape Medpresso Inc, Oncology Nursing Drug Handbook - v3.5.13 requiere la versión de Android al menos Android 5.0+. Por lo tanto, debe actualizar su teléfono si es necesario.

Casi cargado, sobre 1000 descargas. Si lo desea, puede actualizar las aplicaciones que se han descargado o instalado individualmente en su dispositivo Android. Actualizar sus aplicaciones le da permiso de acceso a las funciones más recientes y mejora la seguridad y estabilidad de las aplicaciones

Written especially for nurses caring for patients with cancer, the 2020-2021 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. This essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.

DESCRIPTION
Completely revised and updated, the 2020-2021 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for drugs recently approved by the FDA.

Key Features

- Provides valuable information on effective symptom management, patient education, and chemotherapy administration.
- Completely revised and updated, includes separate chapters on molecular and immunologic/biologic targeted therapies
- Provides fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer
- Offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs
- New drugs include: apalutamide (Erleada™), calaspargase pegol-mknl (Asparlas™), Daunorubicin and cytarabine liposome for injection (Vyxeos®), glucarpidase (Voraxaze®), alpelisib (Piqray®), binimetinib (Mektovi®), dacomitinib (Vizimpro®), Duvelisib (Copiktra®), encorafenib (Braftovi®), erdafitinib (Balversa™), lorlatinib (Lorbrena®), anakinra (Kineret®), baricitinib (Olumiant®), sarilumab (Kevzara®), aprepitant injectable emulsion (Cinvanti®), granisetron hydrochloride extended-release injection (Sustol®), letermovir (Prevymis™), omadacycline (Nuzyra™), meropenem/vaborbactam (Vabomere™), Plazomicin (Zemdri™), baloxavir marboxil (Xofluza™), imipenem/cilastatin sodium/relebactam (Recarbrio™), eravacycline (Xerava™), delafloxacin (Baxdela™)

Faster download with slow internet connectivity